X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
EYP-1901 delivers vorolanib, a selective tyrosine kinase inhibitor formulated in a solid bioerodible insert using EyePoint’s proprietary sustained-release Durasert E™ technology. It is under phase 2 clinical development for the treatment of diabetic macular edema.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, for wet age related macular degeneration.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $230.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 08, 2023
Details:
EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, for wet age related macular degeneration.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 05, 2023
Details:
EyePoint intends to use the net proceeds that it will receive from the offering to advance clinical development of EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, for wet age related macular degeneration.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $201.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 04, 2023
Details:
EYP-1901 (vorolanib) is being developed as a sustained delivery treatment for wet age-related macular degeneration combining a bioerodible formulation of EyePoint's proprietary Durasert® delivery technology (Durasert E™) with vorolanib, a tyrosine kinase inhibitor.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
EYP-1901 (vorolanib) is being developed as an investigational sustained delivery, for maintenance treatment of wet AMD combining a bioerodible formulation of Durasert® delivery technology with vorolanib, a tyrosine kinase inhibitor.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2023
Details:
Positive safety and efficacy data from the DAVIO Phase 1 clinical trial of EYP-1901, a Durasert® delivery technology with vorolanib, a tyrosine kinase inhibitor showed no reports of ocular or drug-related systemic serious adverse events.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2022
Details:
EYP-1901 (vorolanib) is being developed as an investigational sustained delivery treatment combining a bioerodible formulation of EyePoint's proprietary Durasert® delivery technology with vorolanib, a tyrosine kinase inhibitor.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
EYP-1901 is being developed as an investigational sustained delivery treatment, initially in wet age-related macular degeneration (wet AMD) combining a bioerodible formulation of EyePoint's proprietary Durasert® delivery technology with vorolanib, a tyrosine kinase inhibitor.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2022
Details:
EYP-1901 (vorolanib) is an investigational sustained delivery anti-VEGF treatment utilizing a bioerodible formulation of EyePoint's Durasert® drug delivery technology that has been used in four FDA-approved products.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
Under the terms of the new agreement between EyePoint and Equinox Sciences, Betta Pharmaceuticals receives exclusive rights to develop and commercialize EYP-1901(Vorolanib) in China, Hong Kong, Macau and Taiwan. EyePoint will retain global rights in the rest of the world.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: EyePoint Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 04, 2022
Details:
EyePoint intends to use the net proceeds from the offering to advance EYP-1901 into and through Phase 2 clinical trials for wet AMD, DR, and RVO, as well as support its earlier stage pipeline development initiatives, and for general corporate purposes.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cowen and Guggenheim Securities
Deal Size: $115.4 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 19, 2021
Details:
The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential twice-yearly intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2021
Details:
The Phase 1 DAVIO clinical trial is an open-label, dose escalation clinical trial of EYP-1901 that enrolled 17 patients with previously treated wet AMD. Six-month interim data from the Phase 1 DAVIO clinical trial show no reports of ocular SAEs or drug-related systemic SAEs.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2021
Details:
EYP-1901 is delivered via a single intravitreal injection in the physician's office. The primary endpoint of the trial is safety, and key secondary endpoints are best corrected visual acuity and central subfield thickness as measured by optical coherence tomography.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2021
Details:
EyePoint intends to use the net proceeds from the offering for the advancement of EYP-1901 for wet AMD, for pipeline and commercial programs, and for general corporate purposes.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cowen
Deal Size: $115.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 04, 2021
Details:
Results from the study showed no EYPT-1901-related adverse ocular or systemic toxicology findings at any dose level studied in the rabbit model.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: EYP-1901
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
EYP-1901 combines vorolanib with EyePoint’s bioerodible Durasert™ technology as a six-month sustained release intravitreal therapeutic program to reduce injection frequency of available treatments.
Lead Product(s): Vorolanib
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: EyePoint Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: $1.0 million
Deal Type: Licensing Agreement February 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
